IOL | Ophthalmology Innovation Source

Clearsight Innovations

Historically, IOL power formulations are good for average refractive outcomes, but poor for predicting an individual’s refractive outcome. The Mirricon may overcome those issues. The ocular biometer for high-performance IOL power calculations provides “results at the push of a button assuring convenience and easy decisions without great expertise and experience,” Mrochen said. An ongoing proof…

PowerVision

PowerVision’s FluidVision is a shape-changing accommodating IOL that has been implanted in more than 100 patients to date. As patients focus on near objects, one drop of the lens’ fluid moves from the periphery to the center of the lens, changing its shape. When the patient focuses on a distance object, the reverse occurs. PowerVision…

Emmetrope

Emmetrope is developing 3 versions of an accommodating lens: single optic ActaLens, dual optic ActaLens-Duo, and shape-changing optic ActaLens-SC, “the future of accommodative lens technology,” said Phillips. To date, small numbers have been enrolled (n=8), but data looks promising—the monofocal hinged silicone ActaLens is injected into the capsular bag through a small corneal incision and…

AcuFocus

Nick Tarantino, Chief Global Clinical Research & Regulatory Affairs Officer AcuFocus’ newest technology, the IC-8 small aperture IOL, builds on the company’s long-term experience with small aperture optics (it developed the KAMRA lens for presbyopia about 10 years ago). The IC-8 essentially takes the KAMRA inlay from the corneal plane to the lens plane. The…

OIS Overview: Haimovitch, Lachman Share Insights On OIS, MIGs, IOLs, etc

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 040″] Veteran Ophthalmology Scribes Larry Haimovitch of Haimovitch Medical Technology Consultants and Mike Lachman of EyeQ Research put down the pens and pick up the Mics to share their insights on ophthalmology.

PowerVision’s Cheskin Discusses The Potential Of The Company’s Accommodating IOL, FluidVision

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 035″] For 10 years PowerVision has been advancing its accommodating IOL, Flu-idVision. Co-Founder, CEO and President Barry Cheskin explains how the company has kept its focus on someday capturing a huge piece of the IOL market. Podcast Guest Barry Cheskin Barry Cheskin is Co-Founder, President & CEO of PowerVision. Mr. Cheskin…

Assort

Assort is a surgical management system that has insight, hindsight, and foresight, explained Assort Pty. Ltd.’s CEO Noel Alpins, MD. It can be used to analyze all ophthalmic parameters, including intraocular pressure and visual acuities. Assort uses the Alpins method to plan astigmatism surgery and analyze outcomes. Part of the Assort system, the iAssort software,…

i-Optics

[creativ_media type=”vimeo” url=”https://vimeo.com/111856584″] Presenter: Jeroen Cammeraat Jeroen Cammeraat is CEO of i-Optics and investor in the company since 2010. A serial entrepreneur and Senior Executive with 20+ years of global experience in the medical technology and life sciences market. View Full Profile

PowerVision

PowerVision Inc.’s FluidVision, an intraocular lens designed to treat presbyopia and/or cataracts, is the only technology that restores true accommodation, reported company President and CEO Barry Cheskin at the OIS forum. It does so by efficiently harnessing the natural muscular forces of accommodation in the eye to move fluids inside the lens. That fluid movement…

Opening The Door For Premium IOLs

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 017″] OIS stalwart Jack Holladay, MD shares details on the work of a task force comprised of representatives from the American Academy of Ophthalmology and the Food and Drug Administration charged with updating the regulatory agency’s Grid and developing a Guidance Document for Extended Depth of Focus and Accommodating IOLs. The…

FDA Division Directors Detail How Agency Adapts to Innovation

The rush of innovation in ophthalmology – both in drugs and devices – is driving the Food and Drug Administration to adopt guidelines and standards to help expedite approvals. Two key players within the agency, Dr. Wiley Chambers and Dr. Malvina Eydelman, sat down for an open Q&A with Emmett Cunningham, MD, co-chair of OIS@AAO.…

PowerVision

Barry Cheskin discusses PowerVision’s six month data on their pilot study and the beginning their CE mark study. Presenter: Barry Cheskin Barry Cheskin is Co-Founder, President & CEO of PowerVision. Mr. Cheskin has over 20 years of general management experience in the medical device business. View Full Profile